
Marco Galardini appointed W2 professor at TWINCORE
Inaugural lecture on 6 March 2026

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
The LISA Summer School 2026 takes place from 23 August to 11 September 2026. Registration is open until 31 March.

Inaugural lecture on 6 March 2026

Some extension numbers have changed.

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Waqas F, S da Costa L, Zapatero-Belinchón F, Carter-Timofte M, Lasswitz L, van der Horst D, Möller R, Dahlmann J, Olmer R, Geffers R, Gerold G, Olagnier D, Pessler F
Elwy A, Abdelrahman H, Specht J, Ewert G, Friebus-Kardash J, Dhiman S, Falkenstein J, Christ T, Wiebeck E, Shamoon A, Leimkühler N, Gramberg T, Russ A, Kalinke U, Kuang F, Sutter K, Kopf M, Mack M, Hansen W, Nimmerjahn F, Lang K
Zhang Y, Matzaraki V, Vadaq N, Blaauw M, Vos W, Groenendijk A, van Eekeren L, Stalenhoef J, Berrevoets M, Rokx C, Delporte M, Otten T, Joosten L, Xu C, Li Y, Vandekerckhove L, van der Ven A, Netea M
The project is developing iPSC-based therapies for MSMD patients, a genetic disease with mutations in the IFN-γ signaling pathway that lead to severe mycobacterial infections. The aim is to improve the treatment prognosis.
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
The project investigates the factors that determine the species barrier mechanism of HCV and make it impossible to study the infection in animal models. The aim is to use genetic screening systems to develop in vivo models for vaccine research.
By applying statistical genetics methods to pathogen genome sequences, we aim to identify and validate genetic determinants of phenotypes such as pathogenicity, virulence and antibiotic resistance, e.g. in E. coli and P. aeruginosa.
Prof. Martin Schwemmle, Medical Center University of Freiburg
"Decoding Pandemic Influenza Viruses"
„ Finding the needle in the haystack of microbial pangenomes “
Prof. Takoto Makeda
Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Japan
“Host protease-mediated activation of respiratory viruses: From the laboratory bench to the frontlines of infectious disease control”

